Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer

被引：0
|
作者：
Craig A. Vargo
Michael J. Berger
Gary Phillips
Ewa Mrozek
机构：
[1] The Ohio State University Wexner Medical Center,Department of Pharmacy, The James Cancer Hospital and Solove Research Institute
[2] The Ohio State University,Center for Biostatistics
[3] The Ohio State University Wexner Medical Center,Division of Medical Oncology, Department of Internal Medicine
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Everolimus; Adverse events; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2913 / 2918
页数：5
相关论文
共 50 条
  • [21] Intracoronary Stenting And Risk for Major Adverse Cardiac Events during the subsequent first month (ISARMACE)
    Schuhlen, H
    Kastrati, A
    Dirschinger, J
    Schomig, A
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 : TCT54 - TCT54
  • [22] Quality of life in metastatic breast cancer: A systematic review of psychosocial issues and adverse events
    Bedding, Christopher
    Absolom, Kate
    Cardoso, Fatima
    Velikova, Galina
    PSYCHO-ONCOLOGY, 2020, 29 : 25 - 25
  • [23] Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events
    Hurwitz, Herbert
    Saini, Shermini
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S26 - S34
  • [24] Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
    Hansen, Ryan N.
    Ramsey, Scott D.
    Lalla, Deepa
    Masaquel, Anthony
    Kamath, Tripthi
    Brammer, Melissa
    Hurvitz, Sara A.
    Sullivan, Sean D.
    SPRINGERPLUS, 2014, 3 : 1 - 8
  • [25] HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT FOR METASTATIC COLORECTAL CANCER
    Fu, A. Z.
    Zhao, Z.
    Wang, S.
    Gao, S.
    Barber, B.
    Liu, G.
    VALUE IN HEALTH, 2011, 14 (03) : A173 - A173
  • [26] Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms?
    Roca-Alonso, Laura
    Pellegrino, Loredana
    Castellano, Leandro
    Stebbing, Justin
    CARDIOLOGY, 2012, 122 (04) : 253 - 259
  • [27] Bevacizumab in the first-line treatment of metastatic breast cancer
    Cameron, David
    EJC SUPPLEMENTS, 2008, 6 (06): : 21 - 28
  • [28] Bevacizumab in first-line treatment of metastatic breast cancer
    Miles, David
    DRUGS, 2007, 67 (12) : 1800 - 1800
  • [29] BevacizumabIn First-Line Treatment of Metastatic Breast Cancer
    Lesley J. Scott
    Drugs, 2007, 67 : 1793 - 1799
  • [30] Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer
    Heras, P.
    Kritikos, K.
    Hatzopoulos, A.
    Georgopoulou, A. -P.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (06) : 653 - 656
12345